Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2011

01-07-2011 | Original Article

Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells

Authors: Anja Wilmes, David O’Sullivan, Ariane Chan, Clarissa Chandrahasen, Ian Paterson, Peter T. Northcote, Anne Camille La Flamme, John H. Miller

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2011

Login to get access

Abstract

Purpose

Microtubule-stabilizing agents are an important class of anticancer compounds. Peloruside A and laulimalide bind to a different site on the microtubule to taxoid site drugs such as paclitaxel (Taxol®), docetaxel (Taxotere®), ixabepilone (Ixempra®), the epothilones, and discodermolide. The purpose of this study was to examine the synergistic interactions of these drugs when given in combination in relation to the differences in their binding sites on the microtubule.

Methods

Human ovarian carcinoma cells (1A9 cells) and murine T cells were treated with different combinations of microtubule-stabilizing or destabilizing agents. The compounds were given individually and in combination, and the antiproliferative activity was assessed to calculate a combination index (CI) from the equation: CI = D 1/Dx 1 + D 2/Dx 2 in which D 1 and D 2 are the concentrations of drug 1 and drug 2 that when given together give the same response as drug 1 and 2 alone (Dx 1 and Dx 2). Thus, a CI value of less than 1.0 indicates a synergistic effect between the two drugs in which the response to the two drugs given together is greater than the additive response of the two drugs if given on their own.

Results

As anticipated from previous in vitro studies, peloruside A and laulimalide did not synergize with each other. They also failed to synergize with the microtubule-destabilizing agents vinblastine and 2-methoxyestradiol. Peloruside A and laulimalide did, however, synergize with the epothilones, as had been previously shown, but not with docetaxel or discodermolide.

Conclusions

Combining two microtubule-targeting agents with different binding sites does not guarantee a synergistic interaction in cells, and additional factors are likely to be involved. This study highlights the importance of preclinical testing of actual combinations of drugs before proceeding into clinical trials.
Literature
1.
Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26:468–473PubMedCrossRef
2.
Berenbaum MC (1985) The expected effect of a combination of agents: the general solution. J Theor Biol 114:413–431PubMedCrossRef
3.
Blansfield JA, Caragacianu D, Alexander HR III, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14:270–280PubMedCrossRef
4.
Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov 8:783–793PubMedCrossRef
5.
Budman DR, Calabro A (2002) In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 74:41–46PubMedCrossRef
6.
Campone M, Blasinska-Morawiek M, Tekiela A, Koralewski P, Pouget JC, Douville I, Brandely M (2009) Phase II study of vinerelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 63:937–943PubMedCrossRef
7.
8.
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55PubMedCrossRef
9.
Clark EA, Hills PM, Davidson BS, Wender PA, Mooberry SL (2006) Laulimalide and synthetic laulilmalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 3:457–467PubMedCrossRef
10.
Crume KP, Miller JH, La Flamme AC (2007) Peloruside A, an anti-mitotic agent, specifically decreases TNF-α production by LPS-stimulated murine macrophages. Exp Biol Med 232:607–613
11.
Crume KP, O’Sullivan D, Miller JH, Northcote PT, La Flamme AC (2009) Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and peloruside A. J Leukoc Biol 86:949–958PubMedCrossRef
12.
Delord JP, Dalenc F, Pinguet F, Nguyen L, Lochon I, Poublanc M, Chatelut E, Roche H (2007) A phase I-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Oncology 72:322–325PubMedCrossRef
13.
Edelmann JM (2009) Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 10:30–34CrossRef
14.
Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH (2004) Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 64:5063–5067PubMedCrossRef
15.
Gapud EJ, Bai R, Ghosh AK, Hamel E (2004) Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol Pharmacol 66:113–121PubMedCrossRef
16.
Gertsch J, Meier S, Müller M, Altmann KH (2009) Differential effects of natural product microtubule stabilizers on microtubule assembly: Single agent and combination studies with Taxol, epothilone B, and discodermolide. Chem Biol Chem 10:166–175
17.
Giannakakou P, Fojo T (2000) Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy. Clin Cancer Res 6:1613–1615PubMed
18.
Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T (1998) Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer 75:57–63PubMedCrossRef
19.
Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I, Sorensen EJ (2006) Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 70:1555–1564PubMedCrossRef
20.
Han G-Z, Liu Z-J, Shimoi K, Zhu BT (2005) Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 65:387–393PubMed
21.
Honore S, Kamath K, Braguer D, Horwitz SB, Wilson L, Brian C, Jordan MA (2004) Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 64:4957–4964PubMedCrossRef
22.
Huang GS, Lopez-Barcons L, Freeze BS, Smith AB III, Goldberg GL, Horwitz SB, McDaid HM (2006) Potentiation of Taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 12:298–304PubMedCrossRef
23.
Huzil JT, Chik JK, Slysz GW, Freedman H, Tuszynski J, Taylor RE, Sackett DL, Schriemer DC (2008) A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol 378:1016–1030PubMedCrossRef
24.
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265PubMedCrossRef
25.
Khrapunovich-Baine M, Menon V, Verdier-Pinard P, Smith AB III, Angeletti RH, Fiser A, Horwitz SB, Xiao H (2009) Distinct pose of discodermolide in Taxol binding pocket drives a complementary mode of microtubule stabilization. Biochemistry 48:11664–11677PubMedCrossRef
26.
Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429–1437PubMed
27.
Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, Pettus TR, Kaufman MD, Arimoto H, Danishefsky SJ, Smith AB III, Horwitz SB (2000) Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6:1978–1987PubMed
28.
Miller JH, Singh AJ, Northcote PT (2010) Microtubule-stabilizing drugs from marine sponges: focus on peloruside and zampanolide. Mar Drugs 8:1059–1079PubMedCrossRef
29.
Miller VA (1997) Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial. Semin Oncol 24(Suppl 14):S14-15–S14-17
30.
Okuda K, Hirose T, Ishida H, Kusumoto S, Sugiyama T, Ando K, Ohnishi T, Horichi N, Ohmori T, Adachi M (2008) Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 61:829–835PubMedCrossRef
31.
Paterson I, Florence GJ, Gerlach K, Scott JP, Sereinig N (2001) A practical synthesis of (+)-discodermolide and analogues: Fragment union by complex aldol reactions. J Am Chem Soc 123:9535–9544PubMedCrossRef
32.
Photiou A, Shah P, Leong LK, Moss J, Retsas S (1997) In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 33:463–470PubMedCrossRef
33.
Pryor DE, O’Brate A, Bilcer G, Díaz JF, Wang Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou P, Hamel E (2002) The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 41:9109–9115PubMedCrossRef
34.
Robinson MJ, Ronchese F, Miller JH, La Flamme AC (2009) Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro. Immunol Cell Biol 88:291–296PubMedCrossRef
35.
36.
West LM, Northcote PT, Battershill CN (2000) Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 65:445–449PubMedCrossRef
37.
Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH (2007) Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharm 4:269–280PubMedCrossRef
38.
Wilmes A, Rawson P, Peng L, McLauchlan D, Northcote PT, Jordan TW, Miller JH (2010) Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells. Invest New Drugs. doi:10.​1007/​s10637-010-9387-5
Metadata
Title
Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells
Authors
Anja Wilmes
David O’Sullivan
Ariane Chan
Clarissa Chandrahasen
Ian Paterson
Peter T. Northcote
Anne Camille La Flamme
John H. Miller
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1461-3

Other articles of this Issue 1/2011

Cancer Chemotherapy and Pharmacology 1/2011 Go to the issue

Original Article

Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial

Original Article

Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study

Original Article

Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma

Original Article

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

Original Article

Inhibition of N-linked glycosylation by tunicamycin induces E-cadherin-mediated cell–cell adhesion and inhibits cell proliferation in undifferentiated human colon cancer cells

Original Article

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits